nach oben

Cancer Immunology, Immunotherapy

Erschienen in:

10.07.2020 | Original Article

Selective BET-bromodomain inhibition by JQ1 suppresses dendritic cell maturation and antigen-specific T-cell responses

verfasst von: Niklas Remke, Savita Bisht, Sebastian Oberbeck, Jens Nolting, Peter Brossart

Erschienen in: Cancer Immunology, Immunotherapy | Ausgabe 1/2021

Einloggen, um Zugang zu erhalten

Abstract

Bromo- and extra-terminal domain (BET) inhibitors represent potential therapeutic approaches in solid and hematological malignancies that are currently analyzed in several clinical trials. Additionally, BET are involved in the epigenetic regulation of immune responses by macrophages and dendritic cells (DCs), that play a central role in the regulation of immune responses, indicating that cancer treatment with BET inhibitors can promote immunosuppressive effects. The aim of this study was to further characterize the effects of selective BET inhibition by JQ1 on DC maturation and DC-mediated antigen-specific T-cell responses. Selective BET inhibition by JQ1 impairs LPS-induced DC maturation and inhibits the migrational activity of DCs, while antigen uptake is not affected. JQ1-treated DCs show reduced ability to induce antigen-specific T-cell proliferation. Moreover, antigen-specific T cells co-cultured with JQ1-treated DCs exhibit an inactive phenotype and reduced cytokine production. JQ1-treated mice show reduced immune responses in vivo to sublethal doses of LPS, characterized by a reduced white blood cell count, an immature phenotype of splenic DCs and T cells and lower blood levels of IL-6. In our study, we demonstrate that selective BET inhibition by JQ1, a drug currently tested in clinical trials for malignant diseases, has profound effects on DC maturation and DC-mediated antigen-specific T-cell responses. These immunosuppressive effects can result in the induction of possible infectious side effects in cancer treatments. In addition, based on our results, these compounds should not be used in combinatorial regimes using immunotherapeutic approaches such as check point inhibitors, T-cell therapies, or vaccines.

Nur mit Berechtigung zugänglich

Shi X, Liu C, Liu B, Chen J, Wu X, Gong W (2018) JQ1: a novel potential therapeutic target. Pharmazie 73(9):491–493. https://doi.org/10.1691/ph.2018.8480CrossRefPubMed

Filippakopoulos P, Qi J, Picaud S, Shen Y, Smith WB, Fedorov O, Morse EM, Keates T, Hickman TT, Felletar I, Philpott M, Munro S, McKeown MR, Wang Y, Christie AL, West N, Cameron MJ, Schwartz B, Heightman TD, La Thangue N, French CA, Wiest O, Kung AL, Knapp S, Bradner JE (2010) Selective inhibition of BET bromodomains. Nature 468(7327):1067–1073. https://doi.org/10.1038/nature09504CrossRefPubMedPubMedCentral

Delmore JE, Issa GC, Lemieux ME, Rahl PB, Shi J, Jacobs HM, Kastritis E, Gilpatrick T, Paranal RM, Qi J, Chesi M, Schinzel AC, McKeown MR, Heffernan TP, Vakoc CR, Bergsagel PL, Ghobrial IM, Richardson PG, Young RA, Hahn WC, Anderson KC, Kung AL, Bradner JE, Mitsiades CS (2011) BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell 146(6):904–917. https://doi.org/10.1016/j.cell.2011.08.017CrossRefPubMedPubMedCentral

French CA, Miyoshi I, Aster JC, Kubonishi I, Kroll TG, Dal Cin P, Vargas SO, Perez-Atayde AR, Fletcher JA (2001) BRD4 bromodomain gene rearrangement in aggressive carcinoma with translocation t(15;19). Am J Pathol 159(6):1987–1992. https://doi.org/10.1016/S0002-9440(10)63049-0CrossRefPubMedPubMedCentral

Filippakopoulos P, Knapp S (2014) Targeting bromodomains: epigenetic readers of lysine acetylation. Nat Rev Drug Discov 13(5):337–356. https://doi.org/10.1038/nrd4286CrossRefPubMed

Nicodeme E, Jeffrey KL, Schaefer U, Beinke S, Dewell S, Chung C-W, Chandwani R, Marazzi I, Wilson P, Coste H, White J, Kirilovsky J, Rice CM, Lora JM, Prinjha RK, Lee K, Tarakhovsky A (2010) Suppression of inflammation by a synthetic histone mimic. Nature 468(7327):1119–1123. https://doi.org/10.1038/nature09589CrossRefPubMedPubMedCentral

Palucka K, Banchereau J (2012) Cancer immunotherapy via dendritic cells. Nat Rev Cancer 12(4):265–277. https://doi.org/10.1038/nrc3258CrossRefPubMedPubMedCentral

Restifo NP, Dudley ME, Rosenberg SA (2012) Adoptive immunotherapy for cancer: harnessing the T cell response. Nat Rev Immunol 12(4):269–281. https://doi.org/10.1038/nri3191CrossRefPubMedPubMedCentral

Banchereau J, Briere F, Caux C, Davoust J, Lebecque S, Liu YJ, Pulendran B, Palucka K (2000) Immunobiology of dendritic cells. Annu Rev Immunol. https://doi.org/10.1146/annurev.immunol.18.1.767CrossRefPubMed

10.

Banchereau J, Steinman RM (1998) Dendritic cells and the control of immunity. Nature 392(6673):245–252. https://doi.org/10.1038/32588CrossRefPubMed

11.

Sallusto F, Lanzavecchia A (1994) Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha. J Exp Med 179(4):1109–1118CrossRef

12.

Takeda K, Kaisho T, Akira S (2003) Toll-like receptors. Annu Rev Immunol. https://doi.org/10.1146/annurev.immunol.21.120601.141126CrossRefPubMed

13.

West MA, Wallin RPA, Matthews SP, Svensson HG, Zaru R, Ljunggren H-G, Prescott AR, Watts C (2004) Enhanced dendritic cell antigen capture via toll-like receptor-induced actin remodeling. Science 305(5687):1153–1157. https://doi.org/10.1126/science.1099153CrossRefPubMed

14.

Platt CD, Ma JK, Chalouni C, Ebersold M, Bou-Reslan H, Carano RAD, Mellman I, Delamarre L (2010) Mature dendritic cells use endocytic receptors to capture and present antigens. Proc Natl Acad Sci USA 107(9):4287–4292. https://doi.org/10.1073/pnas.0910609107CrossRefPubMed

15.

Knight SC, Iqball S, Roberts MS, Macatonia S, Bedford PA (1998) Transfer of antigen between dendritic cells in the stimulation of primary T cell proliferation. Eur J Immunol 28(5):1636–1644. https://doi.org/10.1002/(SICI)1521-4141(199805)28:05%3c1636:AID-IMMU1636%3e3.0.CO;2-9CrossRefPubMed

16.

Campbell JJ, Butcher EC (2000) Chemokines in tissue-specific and microenvironment-specific lymphocyte homing. Curr Opin Immunol 12(3):336–341CrossRef

17.

Kapsenberg ML (2003) Dendritic-cell control of pathogen-driven T-cell polarization. Nat Rev Immunol 3(12):984–993. https://doi.org/10.1038/nri1246CrossRefPubMed

18.

Appleman LJ, Berezovskaya A, Grass I, Boussiotis VA (2000) CD28 costimulation mediates T cell expansion via IL-2-independent and IL-2-dependent regulation of cell cycle progression. J Immunol 164(1):144–151CrossRef

19.

Cheng J, Montecalvo A, Kane LP (2011) Regulation of NF-kappaB induction by TCR/CD28. Immunol Res 50(2–3):113–117. https://doi.org/10.1007/s12026-011-8216-zCrossRefPubMedPubMedCentral

20.

Watts TH (2005) TNF/TNFR family members in costimulation of T cell responses. Annu Rev Immunol. https://doi.org/10.1146/annurev.immunol.23.021704.115839CrossRefPubMed

21.

Kalinski P, Hilkens CM, Wierenga EA, Kapsenberg ML (1999) T-cell priming by type-1 and type-2 polarized dendritic cells: the concept of a third signal. Immunol Today 20(12):561–567CrossRef

22.

Steinman RM (2003) The control of immunity and tolerance by dendritic cell. Pathol Biol (Paris) 51(2):59–60CrossRef

23.

Matheu MP, Sen D, Cahalan MD, Parker I (2008) Generation of bone marrow derived murine dendritic cells for use in 2-photon imaging. J Vis Exp. https://doi.org/10.3791/773CrossRefPubMedPubMedCentral

24.

Heine A, Held SAE, Daecke SN, Wallner S, Yajnanarayana SP, Kurts C, Wolf D, Brossart P (2013) The JAK-inhibitor ruxolitinib impairs dendritic cell function in vitro and in vivo. Blood 122(7):1192–1202. https://doi.org/10.1182/blood-2013-03-484642CrossRefPubMed

25.

Appel S, Mirakaj V, Bringmann A, Weck MM, Grünebach F, Brossart P (2005) PPAR-gamma agonists inhibit toll-like receptor-mediated activation of dendritic cells via the MAP kinase and NF-kappaB pathways. Blood 106(12):3888–3894. https://doi.org/10.1182/blood-2004-12-4709CrossRefPubMed

26.

Weck MM, Appel S, Werth D, Sinzger C, Bringmann A, Grünebach F, Brossart P (2008) hDectin-1 is involved in uptake and cross-presentation of cellular antigens. Blood 111(8):4264–4272. https://doi.org/10.1182/blood-2006-10-051375CrossRefPubMed

27.

Muller S, Filippakopoulos P, Knapp S (2011) Bromodomains as therapeutic targets. Expert Rev Mol Med. https://doi.org/10.1017/s1462399411001992CrossRefPubMedPubMedCentral

28.

Pardoll DM (2012) The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 12(4):252–264. https://doi.org/10.1038/nrc3239CrossRefPubMedPubMedCentral

29.

Sun Y, Wang Y, Toubai T, Oravecz-Wilson K, Liu C, Mathewson N, Wu J, Rossi C, Cummings E, Wu D, Wang S, Reddy P (2015) BET bromodomain inhibition suppresses graft-versus-host disease after allogeneic bone marrow transplantation in mice. Blood 125(17):2724–2728. https://doi.org/10.1182/blood-2014-08-598037CrossRefPubMedPubMedCentral

30.

Schilderink R, Bell M, Reginato E, Patten C, Rioja I, Hilbers FW, Kabala PA, Reedquist KA, Tough DF, Tak PP, Prinjha RK, de Jonge WJ (2016) BET bromodomain inhibition reduces maturation and enhances tolerogenic properties of human and mouse dendritic cells. Mol Immunol. https://doi.org/10.1016/j.molimm.2016.09.010CrossRefPubMed

31.

Toniolo PA, Liu S, Yeh JE, Moraes-Vieira PM, Walker SR, Vafaizadeh V, Barbuto JAM, Frank DA (2015) Inhibiting STAT5 by the BET bromodomain inhibitor JQ1 disrupts human dendritic cell maturation. J Immunol 194(7):3180–3190. https://doi.org/10.4049/jimmunol.1401635CrossRefPubMedPubMedCentral

32.

Belkina AC, Nikolajczyk BS, Denis GV (2013) BET protein function is required for inflammation: Brd2 genetic disruption and BET inhibitor JQ1 impair mouse macrophage inflammatory responses. J Immunol 190(7):3670–3678. https://doi.org/10.4049/jimmunol.1202838CrossRefPubMedPubMedCentral

33.

Meng S, Zhang L, Tang Y, Tu Q, Zheng L, Yu L, Murray D, Cheng J, Kim SH, Zhou X, Chen J (2014) BET inhibitor JQ1 blocks inflammation and bone destruction. J Dent Res 93(7):657–662. https://doi.org/10.1177/0022034514534261CrossRefPubMedPubMedCentral

34.

Sun Y, Huang J, Song K (2015) BET protein inhibition mitigates acute myocardial infarction damage in rats via the TLR4/TRAF6/NF-κB pathway. Exp Ther Med 10(6):2319–2324. https://doi.org/10.3892/etm.2015.2789CrossRefPubMedPubMedCentral

35.

Wienerroither S, Rauch I, Rosebrock F, Jamieson AM, Bradner J, Muhar M, Zuber J, Muller M, Decker T (2014) Regulation of NO synthesis, local inflammation, and innate immunity to pathogens by BET family proteins. Mol Cell Biol 34(3):415–427. https://doi.org/10.1128/MCB.01353-13CrossRefPubMedPubMedCentral

36.

Liu S, Walker SR, Nelson EA, Cerulli R, Xiang M, Toniolo PA, Qi J, Stone RM, Wadleigh M, Bradner JE, Frank DA (2014) Targeting STAT5 in hematologic malignancies through inhibition of the bromodomain and extra-terminal (BET) bromodomain protein BRD2. Mol Cancer Ther 13(5):1194–1205. https://doi.org/10.1158/1535-7163.MCT-13-0341CrossRefPubMedPubMedCentral

37.

Lehtonen A, Matikainen S, Miettinen M, Julkunen I (2002) Granulocyte-macrophage colony-stimulating factor (GM-CSF)-induced STAT5 activation and target-gene expression during human monocyte/macrophage differentiation. J Leukoc Biol 71(3):511–519PubMed

38.

Heine A, Held SAE, Daecke SN, Riethausen K, Kotthoff P, Flores C, Kurts C, Brossart P (2015) The VEGF-receptor inhibitor axitinib impairs dendritic cell phenotype and function. PLoS ONE 10(6):e0128897. https://doi.org/10.1371/journal.pone.0128897CrossRefPubMedPubMedCentral

39.

Arrighi JF, Rebsamen M, Rousset F, Kindler V, Hauser C (2001) A critical role for p38 mitogen-activated protein kinase in the maturation of human blood-derived dendritic cells induced by lipopolysaccharide, TNF-alpha, and contact sensitizers. J Immunol 166(6):3837–3845. https://doi.org/10.4049/jimmunol.166.6.3837CrossRefPubMed

40.

Wang H, Huang W, Liang M, Shi Y, Zhang C, Li Q, Liu M, Shou Y, Yin H, Zhu X, Sun X, Hu Y, Shen Z (2018) (+)-JQ1 attenuated LPS-induced microglial inflammation via MAPK/NFκB signaling. Cell Biosci. https://doi.org/10.1186/s13578-018-0258-7CrossRefPubMedPubMedCentral

41.

Sallusto F, Schaerli P, Loetscher P, Schaniel C, Lenig D, Mackay CR, Qin S, Lanzavecchia A (1998) Rapid and coordinated switch in chemokine receptor expression during dendritic cell maturation. Eur J Immunol 28(9):2760–2769. https://doi.org/10.1002/(SICI)1521-4141(199809)28:09%3c2760:AID-IMMU2760%3e3.0.CO;2-NCrossRefPubMed

42.

Liu Z, Roche PA (2015) Macropinocytosis in phagocytes: regulation of MHC class-II-restricted antigen presentation in dendritic cells. Front Physiol. https://doi.org/10.3389/fphys.2015.00001CrossRefPubMedPubMedCentral

43.

Mele DA, Salmeron A, Ghosh S, Huang H-R, Bryant BM, Lora JM (2013) BET bromodomain inhibition suppresses TH17-mediated pathology. J Exp Med 210(11):2181–2190. https://doi.org/10.1084/jem.20130376CrossRefPubMedPubMedCentral

44.

Fu F, Li Y, Qian S, Lu L, Chambers FD, Starzl TE, Fung JJ, Thomson AW (1997) Costimulatory molecule-deficient dendritic cell progenitors induce T cell hyporesponsiveness in vitro and prolong the survival of vascularized cardiac allografts. Transpl Proc 29(1–2):1310CrossRef

45.

Georgiev P, Wang Y, Muise ES, Bandi ML, Blumenschein W, Sathe M, Pinheiro EM, Shumway SD (2019) BET bromodomain inhibition suppresses human T cell function. Immunohorizons 3(7):294–305. https://doi.org/10.4049/immunohorizons.1900037CrossRefPubMed

46.

Kaplan MH, Daniel C, Schindler U, Grusby MJ (1998) Stat proteins control lymphocyte proliferation by regulating p27Kip1 expression. Mol Cell Biol 18(4):1996–2003CrossRef

47.

Hogg SJ, Vervoort SJ, Deswal S, Ott CJ, Li J, Cluse LA, Beavis PA, Darcy PK, Martin BP, Spencer A, Traunbauer AK, Sadovnik I, Bauer K, Valent P, Bradner JE, Zuber J, Shortt J, Johnstone RW (2017) BET-bromodomain inhibitors engage the host immune system and regulate expression of the immune checkpoint ligand PD-L1. Cell Rep 18(9):2162–2174. https://doi.org/10.1016/j.celrep.2017.02.011CrossRefPubMedPubMedCentral

48.

Salio M, Cella M, Suter M, Lanzavecchia A (1999) Inhibition of dendritic cell maturation by herpes simplex virus. Eur J Immunol 29(10):3245–3253. https://doi.org/10.1002/(SICI)1521-4141(199910)29:10%3c3245:AID-IMMU3245%3e3.0.CO;2-XCrossRefPubMed

Titel: Selective BET-bromodomain inhibition by JQ1 suppresses dendritic cell maturation and antigen-specific T-cell responses
verfasst von: Niklas Remke
Savita Bisht
Sebastian Oberbeck
Jens Nolting
Peter Brossart
Publikationsdatum: 10.07.2020
Verlag: Springer Berlin Heidelberg
Erschienen in: Cancer Immunology, Immunotherapy / Ausgabe 1/2021
Print ISSN: 0340-7004
Elektronische ISSN: 1432-0851
DOI: https://doi.org/10.1007/s00262-020-02665-x

Neu im Fachgebiet Onkologie

19.04.2024 | EAU 2024 | Kongressbericht | Nachrichten

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Selective BET-bromodomain inhibition by JQ1 suppresses dendritic cell maturation and antigen-specific T-cell responses

Abstract

Neu im Fachgebiet Onkologie

Prostatakarzinom: EU initiiert neues Screeningkonzept

Blasenkarzinom – Biomarker statt Zytologie?

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Adjuvante Brustkrebstherapie: Doppelt hält besser

Update Onkologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2021

NF2 mutation status and tumor mutational burden correlate with immune cell infiltration in meningiomas

Romidepsin (FK228) regulates the expression of the immune checkpoint ligand PD-L1 and suppresses cellular immune functions in colon cancer

Differential immune microenvironmental features of microsatellite-unstable colorectal cancers according to Fusobacterium nucleatum status

Characteristics of patients with EGFR-mutant non-small-cell lung cancer who benefited from immune checkpoint inhibitors

TGF-βR inhibitor SB431542 restores immune suppression induced by regulatory B–T cell axis and decreases tumour burden in murine fibrosarcoma

Body mass index and immune-related adverse events in patients on immune checkpoint inhibitor therapies: a systematic review and meta-analysis

Neu im Fachgebiet Onkologie

Prostatakarzinom: EU initiiert neues Screeningkonzept

Blasenkarzinom – Biomarker statt Zytologie?

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Adjuvante Brustkrebstherapie: Doppelt hält besser

Update Onkologie